SinglePass: Biopsy Tract Closure Device

What this is

A category-level context brief on biopsy tract closure devices, which seal the needle tract after a percutaneous biopsy to reduce post-procedure bleeding and the complications that follow it.

This is a framework for evaluating the category. It is not company-specific analysis: no SinglePass mechanism, design detail, or clinical data is presented here, because none is in scope for this brief.

The three adoption gates

• Evidence: bleeding rates, re-intervention rates, readmissions, and patient selection criteria — judged against standard practice and real-world baselines rather than idealized controls.
• Workflow: the device has to be fast, simple and reliable, or clinicians will not reach for it routinely no matter what the data says.
• Economics: device cost and the reimbursement pathway materially determine uptake.

The costs nobody puts in the deck

Learning curve and added procedure time are consistently under-weighted in a pitch and consistently decisive at the table. A device that works and costs two minutes competes against a practice that already works and costs none.

Named failure modes

• Studies that are weak, or that do not generalize past the enrolling sites.
• Workflow friction from added steps, added time, added complexity.
• Procurement and reimbursement ambiguity.

Disclosure

GigHz holds a personal position or exposure in this company. That is disclosed here because you should weigh it.

Informational only. Not an offer to sell securities or a solicitation to buy, and not financial, medical, legal or tax advice. Past performance does not guarantee future results.

Informational only. Not investment, medical, legal, or tax advice. GigHz or its founder may hold a position in the company discussed — see the disclosure above.

Written and reviewed by Pouyan Golshani, MD — April 2026